Towards a safe and effective chlamydial vaccine: lessons from the eye. by Mabey, David CW et al.
Mabey, DC; Hu, V; Bailey, RL; Burton, MJ; Holland, MJ (2013) To-
wards a safe and effective chlamydial vaccine: Lessons from the eye.
Vaccine, 32 (14). pp. 1572-8. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2013.10.016
Downloaded from: http://researchonline.lshtm.ac.uk/1620434/
DOI: 10.1016/j.vaccine.2013.10.016
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Vaccine 32 (2014) 1572–1578
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
Towards  a  safe  and  effective  chlamydial  vaccine:  Lessons  from
the  eye
David  C.W.  Mabey ∗, Victor  Hu,  Robin  L.  Bailey,  Matthew  J.  Burton,  Martin  J.  Holland
Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, United Kingdom
a  r  t  i  c  l e  i  n  f  o
Article history:
Received 21 May  2013
Received  in revised form
24 September 2013
Accepted  3 October 2013
Keywords:
Chlamydia
Vaccine
Trachoma
Protective immunity
Immunopathology
a  b  s  t  r  a  c  t
As  well  as  being  the  most  common  bacterial  sexually  transmitted  infection,  Chlamydia  trachomatis  (Ct)
is  the  leading  infectious  cause  of  blindness.  The  pathogenesis  of ocular  chlamydial  infection  (trachoma)
is  similar  to that  of  genital  infection.  In the  1960s  the  efﬁcacy  of  Ct vaccines  against  ocular  infection  was
evaluated  in major  ﬁeld  trials  in Saudi  Arabia,  Taiwan,  The  Gambia,  India  and  Ethiopia.  These  trials  showed
that  it was  possible  to induce  short  term  immunity  to  ocular  infection,  and  to  reduce  the  incidence  of
inﬂammatory  trachoma,  by parenteral  immunisation  with  killed  or live  whole  organism  vaccines.  In one
study,  it was  also  shown  that  the  incidence  of  scarring  sequelae  was  reduced  in vaccinated  children.
Detailed  studies  in  non-human  primates  conducted  at this  time  suggested  that  vaccination  could  lead  to
more  severe  inﬂammatory  disease  on subsequent  challenge.  Since  that  time  there  have  been  many  studies
on  the  immunological  correlates  of  protective  immunity  and immunopathology  in ocular  Ct  infection  in
humans  and non-human  primates,  and  on  host genetic  polymorphisms  associated  with  protection  from
adverse  sequelae.  These  have  provided  important  information  to  guide  the  development  and  evaluation
of  a  human  Ct  vaccine.
© 2013  Published  by Elsevier  Ltd.
1. Introduction
Chlamydia trachomatis (Ct) is the commonest bacterial sex-
ually transmitted infection [1]. Because a high proportion of
infected people have no symptoms, screening programmes for
those at risk have been the mainstay of control programmes in
countries where it is prioritised and economically sustainable.
However, these programmes have failed to reduce the number
of reported cases, and it has even been suggested that early
detection and treatment of chlamydial infection increases its inci-
dence by preventing the development of protective immunity
[2]. A vaccine against Ct would be of great public health bene-
ﬁt.
Several reviews have summarised the evidence for protective
immunity to chlamydial infection, and the immunological corre-
lates of protective immunity and immunopathology, in a variety
of animal models [3–9]; but the relevance of these to human
disease is not clear. The evidence for protective immunity, natural
history and immunobiology of genital Ct infection in humans have
also been extensively reviewed [10,11]. The authors concluded
that more prospective studies in women with genital chlamydial
infection are needed to inform development of a safe and effective
∗ Corresponding author. Tel.: +44 2079272297; fax: +44 2079272739.
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chlamydial vaccine, but pointed out that these are logistically and
ethically very difﬁcult to do [5,11].
C. trachomatis also infects the human eye, causing trachoma,
the leading infectious cause of blindness [12–14]. The genomes of
Ct strains isolated from the eye and genital tract are more than 99%
identical [15], and the clinical and pathological ﬁndings of ocular
and genital infection are similar. Infections are often asymptomatic
at both sites, and are characterised by inﬂammation and the pres-
ence of sub-epithelial lymphoid follicles. The damage in both the
eye and genital tract results from ﬁbrosis, which progresses slowly
(over months or years) at the site of inﬂammation.
The eye is more accessible to examination and sampling
than the urethra, cervix or fallopian tubes. There is an extensive
literature on the natural history, immunology and pathogenesis
of human ocular Ct infection. Human challenge studies, detailed
studies on the natural history, pathogenesis and immune response
to experimental ocular infection in humans and non-human
primates,  and the results of several major trachoma vaccine
trials in humans were reported in the 1960s. More recently there
have been many publications on the immunological correlates
of protective immunity and immunopathology following ocular
Ct infection in humans, on the genetics of susceptibility to the
scarring sequelae of ocular infection, and on gene expression at the
site of infection in the conjunctival epithelium [16]. The purpose
of this review is to summarise the state of knowledge concerning
the natural history, immunology and pathogenesis of ocular Ct
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infection in humans and non-human primates (NHPs), for the
beneﬁt of those interested in the development of a vaccine against
Ct; and to suggest how a chlamydial vaccine might be evaluated in
humans.
2. Natural history of human ocular C. trachomatis infection
Human  volunteer studies showed that the follicular keratocon-
junctivitis characteristic of trachoma develops within 2–15 days of
inoculation, depending on the dose inoculated, and resolves over
several months [17,18]. The follicles of trachoma are best seen in
the conjunctiva of the everted upper eyelid (the subtarsal con-
junctiva) and, according to the World Health Organisation case
deﬁnition, follicular trachoma (TF) is present when more than 5
follicles of >0.5 mm diameter are seen in the central area of the sub-
tarsal conjunctiva. In some cases the follicles are accompanied by
intense inﬂammation which obscures the conjunctival blood ves-
sels; intense trachoma (TI) is diagnosed when more than half the
blood vessels are obscured by inﬂammation. Ct bacterial loads are
highest in those with TI [19]. The presence of TF and/or TI deﬁnes
active trachoma. Ct can often be isolated from cases of active tra-
choma but, because follicles can persist for months or years after the
infection has resolved, even the most sensitive nucleic acid detec-
tion systems often fail to identify infection in subjects with active
trachoma.
Some, but not all cases of active trachoma develop conjuncti-
val scarring, but this process usually takes several years. Ct cannot
usually be isolated from subjects with scarring trachoma. In human
volunteer studies, and in experimental infections in non-human
primates, scarring sequelae were not seen following a single infec-
tion [20–24]. In trachoma endemic communities, the prevalence of
scarring increases with age. It is more common in women, who are
more frequently in contact with young children (the main reser-
voir of infection). People with intense inﬂammatory trachoma and
persistent or recurrent Ct infection are more likely to develop scar-
ring [25,26]. As the scarring progresses and the scars contract, the
lashes may  turn inward and rub against the cornea (trachomatous
trichiasis, or TT), which is painful and causes corneal damage that
may  result in blindness.
3.  Protective immunity to C. trachomatis in humans
Experimental studies in humans and NHPs showed that re-
challenge with the same strain of Ct results in an attenuated clinical
response compared to primary infection, with a lower bacterial load
[17,20,21]. In trachoma endemic communities the prevalence of
ocular Ct infection decreases with age, and the highest bacterial
loads are found in young children, suggesting that a degree of pro-
tective immunity develops following natural infection. A study in
a trachoma endemic community in The Gambia, in which mem-
bers of affected households were examined and tested for ocular
Ct infection every two weeks over a 6-month period in the absence
of treatment, showed that the duration of episodes of disease and
of infection was age dependent. The duration of untreated infec-
tion was estimated to be approximately 15 weeks in children aged
0–4 years, and 8 weeks in older children and adults [27,28]. The
estimated incidence of infection was also lower in older individ-
uals. The conclusion from this study is that protective immunity
develops following natural infection, and is associated with both a
reduced incidence and a reduced duration of infection.
4.  Trachoma vaccine trials
Experiments in baboons and in the Taiwanese monkey (Macaca
cyclops) in the 1960s evaluated the protective efﬁcacy of whole
organism  chlamydial vaccines, delivered parenterally, against
ocular infection [21,29]. In both species it was shown that vaccines
can provide short term, strain-speciﬁc protection against ocular Ct
infection, which is of relatively short duration (less than 2 years).
In the Taiwan monkey exposure to a different serotype led to more
severe disease in vaccinated than unvaccinated animals, suggest-
ing that vaccination could lead to immunopathological damage on
subsequent exposure [21].
Large placebo-controlled human trachoma vaccine trials, using
whole organisms administered by intramuscular injection, were
completed in Saudi Arabia, Taiwan, The Gambia, India and Ethiopia
in the 1960s [30–36]. In Saudi Arabia, two doses of a bivalent killed
whole organism vaccine, or placebo, were given to children aged
less than 3 years, some of whom already had trachoma. Three vac-
cine groups were included, who  received high or low dose aqueous
vaccine, or low dose vaccine with adjuvant. Less active trachoma
was seen at 6 and 12 months in children receiving the low dose
aqueous vaccine compared to placebo, but a higher incidence was
found in those who received a higher dose. There was no differ-
ence in active trachoma or ocular Ct infection between vaccine
and placebo arms when the results were pooled, though a reduced
bacterial load (determined by counting chlamydial inclusions in
conjunctival scrapings) was  found in children receiving high dose
aqueous vaccine and vaccine with adjuvant [30,31].
In  the ﬁrst trial in Taiwan four doses of a formalin-inactivated,
alum-absorbed elementary body vaccine made from a local serovar
C isolate, or placebo, was  given to pre-school siblings of children
with active trachoma over a two year period. There was less active
trachoma in vaccinated children (8% vs 18%), but the protective
effect was  no longer seen one year after the ﬁnal dose. Two  sub-
sequent trials used killed whole organism vaccine in mineral oil,
given to primary school children. A bivalent vaccine, containing a
Taiwanese serovar B isolate in addition to the serovar C isolate used
previously serovars, reduced the incidence of active trachoma from
8.8% to 5.1%, but this difference was not signiﬁcant. In a second trial,
of a monovalent vaccine containing only serovar C, there was a sig-
niﬁcantly higher incidence of active trachoma in the vaccinated
group, but no difference between the groups in disease severity
[32,33].
In The Gambia, live vaccines were used [34]. In the ﬁrst trial,
the therapeutic effect of vaccination with a Gambian isolate was
assessed by randomising children with clinical signs of active tra-
choma to receive vaccine or placebo [35]. Eight and 17 weeks after
vaccination there was a signiﬁcant clinical improvement in the vac-
cinated but not the placebo group, and the prevalence of Ct infection
(determined by isolation in eggs) was also reduced in the vacci-
nated group. The protective effect was no longer seen at one year.
In the second and third Gambian trials the prophylactic effect of
vaccination was determined [37]. In the second trial two doses
of a monovalent vaccine, made from a local isolate with a min-
eral oil adjuvant, were given 6 months apart. Six months after the
second dose 17/118 children in the placebo group had acquired
trachoma, compared to 7/117 in the vaccinated groups (p = 0.053).
At 12 months there was  no difference between the groups [37]. In
the third trial two  doses of a bivalent vaccine, containing two “fast
killing” isolates, was  given 3 weeks apart. One of these was  an ocu-
lar isolate from Saudi Arabia, and the other from the USA. At 12 and
24 months there was no signiﬁcant difference in the proportion
of children who  had acquired active trachoma between the vacci-
nated and placebo arms. However, at 24 months the proportion of
children in the placebo group with conjunctival scarring was higher
than in the vaccinated group (18/47 vs 9/55, p = 0.034) [37].
In the Indian trial two  doses of a bivalent, formalin inactivated
vaccine or placebo were given to children aged less than 5 years
without signs of clinical trachoma [36]. Twelve months after the
second dose 26/182 vaccinated children had developed clinical
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trachoma (14%), compared to 32/87 in the placebo group (37%)
(p < 0.01). Among those who acquired trachoma, there was no dif-
ference in severity between vaccinated and control children.
These  trials showed that whole organism vaccines can reduce
ocular Ct infection and active trachoma, but that protection is
short lived and, in some cases, strain-speciﬁc. Most encouragingly
in The Gambia, where the presence of conjunctival scarring was
also recorded, there was evidence that vaccination reduced the
incidence of scarring disease. Trials in non-human primates, in
particular those in the Taiwan monkey, suggested that vaccina-
tion could lead to more severe disease on subsequent exposure;
but there was no convincing evidence that vaccination led to more
severe disease in humans.
Since  the 1960s considerable efforts have been made to develop
a subunit vaccine against Ct, but only one of these has shown
evidence of protection in a NHP [38]. Ct major outer membrane
protein (MOMP), when given parenterally in its native form (i.e.
maintaining its tertiary structure), reduced the bacterial load in
cynomolgus monkeys at the time of peak shedding following ocu-
lar infection (days 3–14). However, it had no impact on the duration
of infection or on the progression of clinical disease. On the other
hand, a live attenuated vaccine, consisting of a plasmid-cured (P-
) clinical serovar A trachoma isolate (A2497) caused a productive
infection, but minimal pathology when inoculated into the eyes
of cynomolgus macaques. A2497P-provided a degree of protec-
tion from infection and clinical disease on subsequent challenge
with the wild type strain [39]. Three of 6 vaccinated monkeys were
resistant to challenge ocular infection and, in the 3 which became
infected, the bacterial load was lower than in control animals. The
3 monkeys that were protected from infection shared a common
MHC class II haplotype. There was no evidence that vaccination led
to more severe disease in animals which succumbed to challenge
infection [39].
5.  Immunological correlates of protective immunity and
immunopathology in humans
The relationship between the immune response and clinical out-
comes in human ocular Ct infection has been studied in longitudinal
cohorts, in which subjects who clear the infection are compared
with those who do not; in case-control studies comparing subjects
with current infection with those with clinical signs of active tra-
choma in the absence of detectable Ct infection (who are presumed
to have recently cleared their infection); and in case-control studies
comparing subjects with scarring trachoma with age- and sex-
matched controls from the same community, who are presumed to
have had a similar lifetime exposure to ocular Ct infection. Among
the many advantages of studying ocular infection are the unam-
biguous phenotype, which can be easily determined by everting
the upper eyelid, and the ability to study immune responses at the
site of infection in the conjunctival epithelium.
5.1. Cohort studies
Tear  ﬂuid or sera from children with trachoma can neutralise
homologous ocular isolates of Ct if incubated with them before
inoculation into the owl monkey eye [40]. Serovar-speciﬁc neu-
tralising epitopes have been mapped to the MOMP  [41]. However,
cohort studies in trachoma endemic communities found no evi-
dence that local anti-chlamydial IgG antibodies in ocular secretions
were associated with a reduced incidence of infection. Indeed, the
presence of anti-chlamydial IgG in ocular secretions was associ-
ated with an increased incidence of active trachoma in this study.
The incidence was lower in subjects with anti-chlamydia IgA anti-
bodies in ocular secretions, but the difference was not statistically
signiﬁcant  [42]. In NHPs reduction in shedding and clearance of Ct
infection was  associated with antibody responses to a limited num-
ber of native proteins (MOMP, PmpD, Hsp60, CPAF, pgp3 and 3 as
yet unidentiﬁed polypeptides) which were slowly acquired as the B
cell immune response matured [43]. Children who spontaneously
resolved ocular Ct infection had higher peripheral blood mono-
nuclear cell (PBMC) proliferative responses to chlamydial antigens
than children with persistent infection and disease [44], whereas
increased conjunctival expression of IL-10 and FOXP3 were associ-
ated with longer episodes of infection [45].
5.2. Case-control studies of active trachoma
Conjunctival gene expression proﬁling showed that T-helper
1 (Th1) (IFN , IL12) cytokine expression was increased in chil-
dren with active trachoma and Ct infection [46,47]. One study
showed that the expression of FOXP3, a marker for T-regulatory
cells, was increased in children with clinical signs of trachoma
in whom infection had resolved [48]. The expression of IL17A is
signiﬁcantly increased in active trachoma [49,50]. IL17A is the sig-
nature cytokine of Th17 cells, a CD4+ T-cell population which act
in an antigen-speciﬁc manner [51], but is also produced by other
cell types such as  T-cells, NK cells, macrophages, neutrophils
[52,53]. IL17A is pro-inﬂammatory and plays an important role in
host immunity to extracellular and some intracellular pathogens. It
may  contribute to ﬁbrosis through several mechanisms, including
epithelial-mesenchymal transition (EMT) and increased collagen
production in a TGF1-dependant manner [54].
In both active and scarring trachoma, conjunctival transcrip-
tome studies showed evidence of prominent innate immune
responses [49,55]. In active disease there was  marked enrichment
of neutrophil and NK cell related transcripts [49]. Given that NK
cells are a signiﬁcant source of the anti-ﬁbrotic and anti-chlamydial
cytokine IFN [56], have a direct anti-ﬁbrotic role in other diseases
such as cirrhosis [57], are important in maintaining the epithe-
lial cell barrier via IL-22 production and are lytic for infected cells
[58], the activity of NK cells and their interaction with adaptive T
cells may  be crucial in the balance between immunity and pathol-
ogy [59]. Many other pathways were also differentially expressed,
including pattern recognition receptors and chemokines such as
neutrophil chemotactic factor CXCL5 [50].
5.3. Case-control studies of scarring trachoma
Serological responses associated with scarring or protection
from scarring have been identiﬁed by genome wide proﬁling, using
an in vitro system expressing 908 open reading frames (ORFs) of the
Ct serovar D genome and plasmid (pORF1-8)) [60]. Responses to 4
antigens were associated with trichiasis (CT414, 667, 695, 706), and
to 8 antigens (CT019, 117, 301, 553, 556, 571, 709) with protection
from trichiasis. These are important ﬁndings that could guide the
selection of antigens to be included in a vaccine, but the results
should be treated with caution, since several immunodominant
antigens were not consistently recognised by the majority of sera,
probably due to conformation of the antigens in the in vitro expres-
sion system. Moreover, antigens recognised by T- as well as B-cells
are likely to be important components of a chlamydial vaccine.
Antibody  responses to CT795 were associated with inﬂam-
matory trachoma, antibodies to CPAF with trichiasis [61], and
antibodies to cHsp60 with scarring [62]; but it is unclear whether
these antibodies have a pathogenic role or are simply mark-
ers of previous infection. Other studies have suggested that
immune responses to cHsp60 may  be protective: PBMC prolifera-
tion responses to cHsp60 were weaker in subjects with conjunctival
scarring than in controls, while the resolution of infection was  asso-
ciated with increased responses [44,63].
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T-helper 2 (Th2) dominated responses have been linked to
ﬁbrotic complications in some infectious diseases, e.g. schisto-
somiasis [64,65]. Adults with conjunctival scarring, compared to
controls, have reduced lymphoproliferative responses and IFN
production following stimulation with Ct EB and some chlamyd-
ial antigens, but an increased number of IL-4 producing cells in
response to cHsp60 [63,66]. This provides some support for the
hypothesis that individuals with scarring may  have weaker Th1
cell-mediated responses to Ct, leading to prolonged infection and
inﬂammation, possibly as a result of Th2 responses with pro-
ﬁbrotic effects. Studies comparing the conjunctival transcriptome
by microarray and RT-PCR in subjects with scarring trachoma and
matched controls found no evidence of polarisation towards Th2
responses [49,55,67,68]. Th2 cytokine levels in tear ﬂuid were not
increased in scarred individuals [69], and cytokine production in
response to chlamydial antigens was no different in PBMC from
cases and controls [56].
We  identiﬁed a higher frequency of IL-10 [66] expression in
PBMCs from cases of scarring than controls, but no differences
in T regulatory cell subsets [56]. IL-10 is produced by several T
cell subsets, and is not well accommodated by the T helper cell
dichotomy. A case control study identiﬁed a single nucleotide
polymorphisms (SNP) in the IL-10 gene that was associated with
scarring [66,70–73]. Gene expression studies in the conjunctival
epithelium of subjects with active trachoma who were heterozy-
gous for a SNP in the transcribed portion of the IL-10 gene found that
the haplotype associated with scarring was transcribed more efﬁ-
ciently than the other allele, suggesting that increased expression
of IL-10 predisposes to adverse sequelae of Ct infection [74].
Expression  of pro- inﬂammatory mediators such as psoriasin-
1 (S100A7), IL1B and CXCL5 is upregulated in scarring trachoma
[55,68]. These factors induce neutrophil chemotaxis, and their
expression was particularly increased in inﬂamed cases. Expression
of the antimicrobial peptide S100A7 was associated with recur-
rent trichiasis [75]. The importance of the chemokine response in
trachoma is further supported by the ﬁnding that genetic varia-
tion across the IL8 locus, deﬁned by haplotypes of multiple SNPs,
was associated with scarring [76]. TNF is a key cytokine in acute
inﬂammation and has been associated with scarring trachoma in
several studies: elevated levels have been found in tear ﬂuid, and
increased secretion from PBMC from scarred subjects stimulated
with chlamydial elementary bodies [69,70,77,78]. Increased con-
junctival transcript levels of TNFA, as well as IL1B, have also been
associated with active disease and Ct infection [46,47,79].
Scarring develops when normal tissue architecture is disrupted
and replaced by excessive connective tissue through the abnormal
accumulation of extracellular matrix (ECM). Tissue damage [80]
can be mediated through a variety of cell types and mechanisms.
Neutrophil inﬁltration appears important in trachoma: neutrophils
have been identiﬁed in conjunctival biopsies; produce toxic reac-
tive oxygen and nitrogen species which damage host tissue in
animal models of genital tract infection; and can produce matrix
metalloproteinases (MMPs) [81,82]. The archetypal and abundant
Th1 cytokine IFN (also produced by NK cells), considered to be
central to chlamydial control, is also an inducer of MMPs  [83].
The  MMPs are a group of more than 25 endopeptidases with
multiple, complex functions. While MMPs  are required for nor-
mal tissue homeostasis, there is also evidence that they play a
role in the pathogenesis of a range of inﬂammatory-ﬁbrotic dis-
eases [84–86], disrupting the basement membrane and aiding the
recruitment of inﬂammatory cells [87]. MMPs  have wide-ranging
effects on inﬂammatory and immune processes, such as modulat-
ing chemokine activity and activation of TGF, IL-1 and TNF [88].
They are known to be important in a number of ocular surface dis-
eases, and inhibition of MMP  activity has been shown to reduce
conjunctival scarring after glaucoma surgery [89].
MMP9 is part of the neutrophil lysosome, and mediates epithe-
lial dissolution through degradation of type IV collagen [82].
Children with active trachoma have increased amounts of conjunc-
tival MMP9  (determined by immunohistochemistry, zymography
and gene expression analysis) [46,90]. Scarring trachoma is associ-
ated with increased expression of MMP9 and a coding SNP that is
adjacent to the active binding site of the MMP9 enzyme [46,68,91],
and with differential expression of MMPs 7, 9, 10 and 12 and
tissue inhibitor of MMP  (TIMP)-1; recurrence of trichiasis after
surgery is associated with an altered MMP1/TIMP1 transcript ratio
[55,67,68,92].
Scar tissue in trachoma probably originates from activated
ﬁbroblasts which are stimulated to produce collagen by proﬁ-
brogenic mediators (TGF-, PDGF, CTGF and bFGF) [50,93,94].
Chemokines have also been shown to act as ﬁbrogenic mediators, in
particular, the CC- and CXC-chemokine families, and various mem-
bers of these families have been associated with scarring, including
the pro-ﬁbrogenic CCL18 [50,55,69,87].
5.4. Implications for a vaccine against genital Ct infection
Since the pathology of Ct infection is similar in the eye and
genital tract [4,16], and both are part of the common mucosal
immune system, it is likely that similar processes lead to resolution
of infection and/or the development of scarring sequelae at each
site. The few studies that have been conducted on the immuno-
logical correlates of protective immunity and immunopathology in
human genital Ct infection have reached broadly similar conclu-
sions to those of studies in the eye [10,95–97]. Local, endocervical
IgA antibodies appear to be protective [95], and stronger Th-1 type
cell-mediated immune responses to Ct antigens are seen in the
peripheral blood of subjects who  do not have sequelae [96,97].
An  important difference between ocular and genital infection
is that in the eye, the damaging sequelae occur at the site of the
initial infection, the conjunctival epithelium. By contrast, in the
female genital tract the major sequelae develop in the fallopian
tubes and not at the cervix, which is the site of inoculation. Impair-
ment of immunological barriers to ascending infection may  explain
the association between HIV infection and chlamydial PID [98];
no association has been reported between HIV and trachoma. A
vaccine which prevented Ct infection from spreading to the upper
genital tract could be effective in preventing sequelae in the female
genital tract.
6.  How would a chlamydial vaccine be evaluated in
humans?
6.1.  Vaccine efﬁcacy
The  purpose of a chlamydial vaccine is to prevent the seque-
lae of Ct infection: PID, infertility, ectopic pregnancy and blinding
trachoma. An effective chlamydial vaccine could prevent primary
infection, prevent re-infection, modify disease progression follow-
ing infection, or reduce transmission by reducing bacterial load or
the duration of infection.
Phase  II studies could evaluate vaccine immunogenicity, safety
and efﬁcacy in preventing Ct infection in human volunteers. Human
challenge experiments with Ct have not been reported since the
ocular challenge studies more than 50 years ago, but urethral chal-
lenge studies in male volunteers may  be possible; there is an
extensive literature on urethral challenge of human volunteers
with Neisseria gonorrhoeae.
The  primary endpoint for phase III trials would probably be Ct
infection. The frequency of sampling would need to be determined
and, in the case of genital infection, treatment would need to be
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given as soon as infection was detected. In the case of ocular infec-
tion in trachoma endemic communities this would not necessarily
be the case, since the recommended control strategy is annual mass
treatment of endemic communities or households.
Phase IV trials could aim to evaluate vaccine efﬁcacy in pre-
venting PID, but this would be particularly challenging, given the
difﬁculty in making an accurate diagnosis. Improved diagnostic
tests (biomarkers or imaging) will be needed. Evaluating efﬁcacy
in preventing infertility and ectopic pregnancy would require pro-
longed follow up and a large sample size. Phase IV trials will be
confounded by the necessity to treat subjects and their partners as
soon as infection is diagnosed.
Vaccine  efﬁcacy in preventing infection, or reducing inﬂamma-
tion, the duration of infection or the incidence and progression of
scarring could be easily evaluated in a trachoma endemic com-
munity, by frequent examination of the subtarsal conjunctiva. The
incidence and progression of conjunctival scarring can be deter-
mined using an ocular microscope (slit lamp). Our recent studies
have shown that confocal microscopy can identify conjunctival
scarring at an early stage, before it is clinically apparent [99].
6.2.  Vaccine safety
The  evidence from trachoma vaccine trials in monkeys and
humans has been interpreted as showing that vaccination can lead
to more severe inﬂammatory disease following re-challenge with
a different serovar of Ct As discussed above, the evidence for this
from human trials is not convincing; and in the only vaccine trial
in which scarring was included as an endpoint, its prevalence was
reduced in the vaccinated group. Nevertheless, the spectre of an
immunopathological response to chlamydial vaccination will not
be easily laid to rest.
It  would clearly not be possible to compare disease severity in
vaccinated human volunteers and those receiving placebo, since
there would be an ethical imperative to treat as soon as infec-
tion was detected. Ensuring that vaccination does not lead to more
severe PID on subsequent exposure to infection will be difﬁcult
until we have better diagnostic tests. Ensuring that it does not lead
to an increased incidence of infertility or ectopic pregnancy will
require a large sample size and prolonged follow up. On the other
hand, it would be relatively easy to study the impact of vaccination
on the severity of inﬂammatory disease in the eye, and on the inci-
dence or progression of scarring, through frequent examination of
study subjects in trachoma endemic communities.
7. Conclusions
The development of a vaccine against Ct has been held back
by the widely held belief that whole organism trachoma vac-
cines enhanced disease severity on subsequent ocular challenge.
There is no convincing evidence of this from human vaccine tri-
als. The evidence comes from studies in non-human primates, in
whom increased inﬂammation was seen in vaccinated animals;
but the development of scarring sequelae was not evaluated in
these studies. Recent studies in trachoma endemic populations
have identiﬁed new vaccine candidate antigens, immunological
pathways associated with disease resolution and with progressive
ﬁbrosis, and biomarkers which predict the outcome of infection.
Our understanding of pathogenesis is likely to advance rapidly now
that it is possible to genetically manipulate Chlamydia [100]. This
new knowledge is likely to hasten the development of a safe and
effective chlamydial vaccine, which could be easily evaluated in
trachoma endemic communities. Careful thought would need to
be given to the recruitment of study subjects since, in communities
with  a high prevalence, primary infection is likely to occur in early
childhood.
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